全文获取类型
收费全文 | 355篇 |
免费 | 17篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 3篇 |
妇产科学 | 21篇 |
基础医学 | 59篇 |
口腔科学 | 6篇 |
临床医学 | 19篇 |
内科学 | 64篇 |
皮肤病学 | 1篇 |
神经病学 | 25篇 |
特种医学 | 64篇 |
外科学 | 18篇 |
综合类 | 2篇 |
预防医学 | 14篇 |
眼科学 | 4篇 |
药学 | 29篇 |
肿瘤学 | 42篇 |
出版年
2021年 | 9篇 |
2020年 | 3篇 |
2019年 | 4篇 |
2018年 | 7篇 |
2017年 | 7篇 |
2016年 | 10篇 |
2015年 | 9篇 |
2014年 | 5篇 |
2013年 | 14篇 |
2012年 | 19篇 |
2011年 | 20篇 |
2010年 | 14篇 |
2009年 | 10篇 |
2008年 | 18篇 |
2007年 | 23篇 |
2006年 | 19篇 |
2005年 | 25篇 |
2004年 | 16篇 |
2003年 | 13篇 |
2002年 | 17篇 |
2001年 | 11篇 |
2000年 | 13篇 |
1999年 | 10篇 |
1998年 | 2篇 |
1997年 | 3篇 |
1990年 | 5篇 |
1989年 | 15篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 3篇 |
1983年 | 3篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 3篇 |
1975年 | 1篇 |
1974年 | 4篇 |
1973年 | 2篇 |
1971年 | 2篇 |
1970年 | 4篇 |
1969年 | 1篇 |
1967年 | 3篇 |
1966年 | 1篇 |
1961年 | 2篇 |
1960年 | 1篇 |
1958年 | 1篇 |
1939年 | 1篇 |
1938年 | 1篇 |
1937年 | 1篇 |
1936年 | 1篇 |
排序方式: 共有374条查询结果,搜索用时 15 毫秒
141.
142.
Oliver J. Ott MD Ruediger Schulz-Wendtland Wolfgang Uter Annette Pfahlberg Matthias W. Beckmann Rolf Sauer Vratislav Strnad 《Strahlentherapie und Onkologie》2005,181(10):638-644
PURPOSE: To investigate the incidence of fat necrosis, breast tissue fibrosis and breast pain after conserving surgery and accelerated partial-breast irradiation (APBI, group A), whole-breast external-beam irradiation (EBRT, group B), or EBRT combined with an interstitial boost (EBIB, group C) in women with breast cancer. PATIENTS AND METHODS: 85 patients who received breast-conserving therapy from 02/2000 to 03/2002 were analyzed. 30 patients received EBRT, 33 patients APBI, and 22 patients EBIB. Median follow-up was 35.5, 35.0, and 37.5 months, respectively. Fat necrosis was detected and rated by mammograms, fibrosis and pain were clinically rated with the LENT-SOMA scores. RESULTS: The incidence of fat necrosis was 15.3% for all patients; and 15.2%, 20.0%, and 9.0% for groups A, B, and C, respectively. The 3-year fat necrosis-free survival probability was 83%, 76%, and 95% (difference not significant). The mean time to first diagnosis of fat necrosis was 25.6, 26.2, and 26.0 months. No patient needed surgical intervention because of fat necrosis-related pain. Fibrosis was present in 27.3%, 63.3%, and 77.3% (p < 0.001), breast pain in 9.0%, 33.4%, and 18.1% (p < 0.05). CONCLUSION: Asymptomatic fat necrosis is a common finding after both percutaneous and interstitial irradiation after breast-conserving surgery. This analysis did not support the hypothesis that APBI with multicatheter implants leads to higher rates of fat necrosis, fibrosis, or pain. 相似文献
143.
144.
145.
Jakub Vysloužil Petr Doležel Martina Kejdušová Vratislav Košťál Ludvík Beneš 《Pharmaceutical development and technology》2016,21(2):214-221
The aim of the study was to prepare PLGA microparticles for prolonged release of mirtazapine by o/w solvent evaporation method and to evaluate effects of PVA concentration and organic solvent choice on microparticles characteristics (encapsulation efficiency, drug loading, burst effect, microparticle morphology). Also in vitro drug release tests were performed and the results were correlated with kinetic model equations to approximate drug release mechanism. It was found that dichloromethane provided microparticles with better qualities (encapsulation efficiency 64.2%, yield 79.7%). Interaction between organic solvent effect and effect of PVA concentration was revealed. The prepared samples released the drug for 5 days with kinetics very close to that of zero order (R2?=?0.9549 – 0.9816). According to the correlations, the drug was probably released by a combination of diffusion and surface erosion, enhanced by polymer swelling and chain relaxation. 相似文献
146.
Kafka V 《Clinical biomechanics (Bristol, Avon)》2002,17(1):73-80
147.
The role of pulsed-dose-rate brachytherapy in previously irradiated head-and-neck cancer 总被引:1,自引:0,他引:1
PURPOSE: The purpose of this prospective study was to analyze the value of interstitial pulsed-dose-rate (PDR) brachytherapy (iBT) with regard to local control and the incidence of side effects in patients with head-and-neck cancer in a previously irradiated area. METHODS AND MATERIALS: From October 1997 to September 2001, 43 patients with head-and-neck cancer in a previously irradiated area (31 patients with recurrent cancer) were treated with iBT alone or in combination with external beam radiation. Thirty-four of 43 patients received interstitial PDR brachytherapy (DREF=20-60 Gy) as part of their curative treatment regimen alone or in combination with external radiation. Nine patients were implanted for palliative purposes. The pulses were delivered 24 h/day with a time interval of 1 h between two pulses. The dose per pulse (dp) ranged from 0.4-0.7 Gy. Sixteen of 43 (37%) patients also received cisplatin or carboplatin with 5-fluorouracil during the time of the iBT. Additionally 20/43 (47%) patients were treated with interstitial hyperthermia. Thirteen of 43 (30%) patients received external beam radiation in a dose range from 20-67 Gy. A follow-up of all patients was done to analyze local control and survival, and acute and delayed toxicity. This analysis was performed after a median follow-up of 24 months (6-48 months). RESULTS: Local tumor control was achieved in 34 of a total of 43 patients (79%) and in 30/34 patients (88%) treated for curative intention. Distant metastases were observed in 5/43 (12%) patients. The 2-year local recurrence-free survival rates, disease-free survival rates, and overall survival rates according to the Kaplan-Meier method for all patients were 68%, 62%, and 49%, respectively, and for patients treated with curative intention they were 80%, 77% and 66%, respectively. There was no statistical difference in the probability of local recurrence in patients subgrouped by recurrent tumor vs. secondary primary, tumor size, grading and lymphangiosis. The application of chemotherapy or hyperthermia did not have significant influence on the therapy results. Soft tissue necrosis was the only serious side effect seen in 2/43 patients (4.7%). No other serious side effects were observed. CONCLUSIONS: Interstitial pulsed-dose-rate brachytherapy for patients with previously irradiated head-and-neck cancer is an effective therapy with minimal toxicity. The role of chemotherapy and hyperthermia in these patients remains unclear. Further randomized studies with larger patient numbers are necessary to draw a definite conclusion. 相似文献
148.
PurposeTo assess the long-term results of protocol-based pulsed-dose-rate (PDR) interstitial brachytherapy (iBT) in 385 patients with head and neck cancer who underwent PDR-iBT preferably after minimal, nonmutilating surgery.Methods and MaterialsFrom 1997 to 2009, a total of 385 patients received protocol-based PDR-iBT for head and neck cancer. Brachytherapy was preceded by surgery in most of our patients (326/385, 84.7%). Altogether, 246 of 385 patients (63.9%) received iBT alone and 135 of 385 patients (36.1%) in combination with external beam radiation therapy. The analysis was done after a median followup of 63 months.ResultsThe 5-, 10-, and 15-year local relapse-free survival rates according to Kaplan–Meier test for all analyzed patients were 85.8%, 83.1%, and 80.2%, respectively. The 5-, 10-, and 15-year overall survival and disease-free survival rates were 68.9%, 52.2%, and 44.1%, and 81.3%, 79.3%, and 76.3%, respectively. For N0-/N1- vs. N2-patients, we observed significantly different 5-year local recurrence-free survival rates with values of 92.3% and 73.7%, respectively (p = 0.007). No other patient or treatment-related parameters had a significant influence on treatment results. Serious late side effects, such as soft tissue or bone necrosis, were observed in 39 of 385 patients (10.2%) and 18 of 385 patients (4.9%), respectively.ConclusionsThe PDR-iBT with 0.4–0.7 Gy each hour, 24 h per day for patients with head and neck cancer is a proven, effective, and safe treatment method with excellent long-term data. 相似文献
149.
150.